IM Cannabis regains Nasdaq $1 share-price compliance

IM Cannabis Corp. (IMCC) regained compliance with Nasdaq’s $1.00-per-share minimum bid-price requirement after its ordinary shares had a closing bid price of $1.00 or greater for 18 consecutive business days, from August 27 to September 22, 2026.

Rhea-AI Filing Summary

IM Cannabis Corp. (IMCC) regained compliance with Nasdaq’s $1.00-per-share minimum bid-price requirement after its ordinary shares had a closing bid price of $1.00 or greater for 18 consecutive business days, from August 27 to September 22, 2026. Nasdaq notified the company on September 23, 2026, and considers the bid-price deficiency matter closed.

Key Figures

Minimum bid price requirement: $1.00 per share Compliance period: 18 consecutive business days

2 metrics

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2)

Compliance period 18 consecutive business days August 27 to September 22, 2026; closing bid price was $1.00 or greater

Key Terms

minimum bid price requirement, closing bid price, Nasdaq Listing Rule 5550(a)(2)

3 terms

minimum bid price requirement market

"regained compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

closing bid price market

"the closing bid price of the Company’s ordinary shares"

The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.

Nasdaq Listing Rule 5550(a)(2) regulatory

"set forth in Nasdaq Listing Rule 5550(a)(2)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did IMCC regain Nasdaq’s minimum bid-price compliance?

IMCC’s ordinary shares had a closing bid price of $1.00 or greater for 18 consecutive business days, from August 27 to September 22, 2026.

What does IM Cannabis expect to retain or sell after its pending transactions?

After completion of the pending transactions announced on August 17, 2026, IM Cannabis expects to retain its Israeli medical cannabis operations, while its German operations will be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/23/2026 - 04:16 PM Accepted by SEC EDGAR 09/23/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026 (Report No. 3)

Commission File Number: 001-40065

 
IM Cannabis Corp.
(Exact Name of Registrant as Specified in Charter)

Kibbutz Glil Yam, Central District, Israel 4690500
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

On September 23, 2026, IM Cannabis Corp. (the “Company”) issued a press release titled: “IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement”. A copy of this press release is furnished herewith as Exhibit 99.1

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-296637, 333-293236, 333-289571 and 333-288346 ) filed with the SEC to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1	Press Release dated September 23, 2026, titled “IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement”.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IM CANNABIS CORP.
	(Registrant)
Date: September 23, 2026	By:	/s/ Oren Shuster
	Name:	Oren Shuster
	Title:	Chief Executive Officer and Director

Exhibit 99.1

IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement

VANCOUVER and GLIL YAM, Israel, September 23, 2026 - IM Cannabis Corp. (“IMC” or the “Company”) (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced that on September 23, 2026, it received written notice from Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was $1.00 per share or greater for the 18 consecutive business days from August 27 to September 22, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

About IM Cannabis Corp.

IMCC (Nasdaq: IMCC) is an international company currently operating a medical cannabis platform serving patients in Israel and, through Adjupharm GmbH, Germany. Following completion of the pending transactions announced by the Company on August 17, 2026, the Company expects to retain its Israeli medical cannabis operations and the German operations will be sold.

The IMCC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality control of IMCC’s products throughout the value chain.

Company Contact:

Michal Efraty

Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com

Oren Shuster, Chief Executive Officer

IM Cannabis Corp.

info@imcannabis.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 5.1 KB